Stock
GSK plc American Depositary Shares (Each representing two Ordinary Shares) GSK
Overview
GSK market data
Price History
GSK price chart · 1M
- O
- 49.42
- H
- 49.49
- L
- 49.02
- C
- 49.23
- Vol
- 242,518.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $49.42
- Previous Close
- $49.65
- Day High
- $49.49
- Day Low
- $49.02
- 52 Week High
- $55.29
- 52 Week Low
- $47.86
- 7 Day Return
- -1.93%
- 30 Day Return
- -4.29%
- 90 Day Return
- -5.96%
- 1 Year Return
- -1.68%
- Daily Notional Volume
- $11.9M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 15.68 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.39 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.28 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 3.9% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 14.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1,455.00 – $2,282.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $75.6B · P/B 4.51 · P/S 2.28.
Company News
10 captured
Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive LandscapeGlobenewswire Inc ·
Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightGlobenewswire Inc ·
Managing Service Providers Including CRO and CMOs Oversight to Comply with ICH GCP R3 Scheduled for October 14–15, 2027Globenewswire Inc ·
GSK Inks $750M Deal to Add Experimental Blood Cancer TherapyZacks Investment Research ·
Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsightGlobenewswire Inc ·
Why Is GSK Stock Gaining Monday?Benzinga ·
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent CliffZacks Investment Research ·